Investors who might be looking to invest in pharmaceutical stocks could have a look at the Aurinia Pharmaceuticals (NASDAQ: AUPH) stock. The stock has gained considerable momentum in recent days and especially so after it announced its Q4 2020 financial results along with the same for the full year 2020.
The President and Chief Executive Officer of the company Peter Greenleaf spoke about the company’s progress over the past year as well. He said that during the period Aurinia has managed to develop into a fully integrated biopharmaceutical firm.
He went on to add that the approval of LUPKYNIS from the United States Food and Drug Administration and the subsequent launch of the product is an indication of the company’s progress during the period. These are all highly critical developments and it is understandable why the stock gained momentum in recent days. Hence, it might be a good idea for investors to perhaps keep track of the Aurinia stock.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.